Publications by authors named "P Schouten"
Article Synopsis
- Ovarian cancer patients with Homologous Recombination Deficiency (HRD) may benefit from PARP inhibitor therapy after platinum chemotherapy, and predicting this benefit through whole slide images (WSIs) could provide a quicker and less costly alternative to molecular tests.
- A Deep Learning (DL) model was trained on H&E stained WSIs using a specific HRD ground truth, and it was tested on a separate cohort to see how well it predicted HRD status and the benefit of olaparib treatment.
- Although the model showed potential, with a significant improvement in progression-free survival (PFS) for HRD positive patients treated with PARP inhibitors, its overall prediction accuracy was lower than desired, indicating that further
Spectroradiometry, radiometry, and dosimetry are employed for the measurement of ultraviolet radiation (UVR) irradiance and non-ionizing exposure. Different types of UVR dosimeter have been developed for measuring personal and environmental UVR exposures since film dosimetry was pioneered in the 1970s. An important type of dosimeter is the thin film variant, which contains materials that undergo changes in optical absorbance when exposed to UVR.
View Article and Find Full Text PDFImportance: Testing for homologous recombination deficiency is required for the optimal treatment of high-grade epithelial ovarian cancer. The search for accurate biomarkers is ongoing.
Objective: To investigate whether progression-free survival (PFS) and overall survival (OS) of patients with high-grade epithelial ovarian cancer treated with maintenance olaparib or placebo differed between patients with a tumor BRCA-like genomic profile and patients without a tumor BRCA-like profile.
PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer, who were germline BRCA1 and BRCA2 wild type. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the prognostic significance of BRCA1-related biomarkers in young, node-negative, chemotherapy-naïve triple-negative breast cancer (TNBC) patients, focusing on how these biomarkers influence overall survival outcomes.
- It included 485 Dutch women diagnosed with TNBC under age 40, assessing their BRCA1 status and tumor-infiltrating lymphocytes (sTILs) to determine outcomes over a 15-year period.
- Results showed that patients with pathogenic germline BRCA1 mutations had worse survival rates compared to those without alterations, but higher levels of sTILs significantly improved overall survival, particularly in patients with tumor BRCA1 promoter methylation.